{
  "id": 2994834,
  "title": "Symbiotec Pharmalab IPO sees subscription at 0.70x by mid-afternoon",
  "url": "https://urgent.news/2026/08/24/symbiotec-pharmalab-ipo-sees-subscription-at-0-70x-by-mid-afternoon",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T10:20:15.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/symbiotec-pharmalab-ipo-sees-subscription-at-070x-by-mid-afternoon/article71384017.ece"
  },
  "original_language": "en",
  "account": null,
  "summary": "Symbiotec Pharmalab Ltd's IPO saw a subscription rate of 0.70 times by the end of the first day of subscription. The ₹1,757 crore issue, priced between ₹938–988 per share, was offered in a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore. The employee reservation portion led with a subscription of 1.19 times, while Non-Institutional Investors (NII) in the sub-₹10 lakh bracket were the only open-market category to fully subscribe at 1.33 times. Retail Individual Investors and Qualified Institutional Buyers (QIB) were the weakest segments, with subscription rates of 0.82 times and 0.35 times respectively.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Business Standard IN",
        "title": "Symbiotec Pharmalab raises ₹526 cr from anchor investors; IPO opens Aug 24",
        "url": "https://urgent.news/2026/08/21/symbiotec-pharmalab-raises-526-cr-from-anchor-investors-ipo-opens-aug",
        "published": "2026-08-21T16:28:27.000Z"
      },
      {
        "outlet": "Hindu BusinessLine",
        "title": "Symbiotec Pharmalab raises Rs 526 cr from anchor investors; IPO opens on Aug 24",
        "url": "https://urgent.news/2026/08/21/symbiotec-pharmalab-raises-rs-526-cr-from-anchor-investors-ipo-opens",
        "published": "2026-08-21T16:29:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}